Program
evorpacept
Also written as “Evorpacept (ALX148)” and “Evorpacept”.
Its studies are mostly in Squamous Cell Carcinoma of Head and Neck · Breast Neoplasms · Stomach Neoplasms · Neoplasm Metastasis · Urinary Bladder Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ALX Oncology | 83 open or running | phase 3since Jul 27, 2021 | Dec 15, 2016 | Dec 2027phase 2 · NCT07007559 |
| Jazz Pharmaceuticals | 10 open or running | phase 2since Aug 23, 2021 | Aug 23, 2021 | none ahead |
Also a collaborator on its studies: Eli Lilly and Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 15, 2016First study: phase 1 study in Neoplasm MetastasisNew to ALX OncologyALX Oncology · NCT03013218 · 174 enrolled · United States, South Korea
- Jun 2, 2020Phase 1 study in Higher Risk Myelodysplastic SyndromesALX Oncology · NCT04417517 · 65 enrolled · United States, South Korea, Spain
- Dec 15, 20202 phase 2 studies in Head and Neck NeoplasmsALX Oncology · NCT04675333, NCT04675294
- Feb 11, 2021Phase 1 study in Leukemia, Myeloid, AcuteALX Oncology · NCT04755244 · 14 enrolled · United States
- Jul 27, 2021Phase 3 study in Stomach NeoplasmsALX Oncology · NCT05002127 · 127 enrolled · United States, Australia, Belgium and more
- Aug 23, 2021Jazz Pharmaceuticals's first study: phase 2 study in HER2-expressing CancersNew to Jazz PharmaceuticalsJazz Pharmaceuticals · NCT05027139 · 52 enrolled · United States
- Aug 30, 2022Phase 1 study in Urinary Bladder NeoplasmsALX Oncology · NCT05524545 · 36 enrolled · United States
- May 22, 2025Phase 2 study in Breast NeoplasmsALX Oncology · NCT07007559 · 120 planned · United States, Canada, France and more
Ahead
- Dec 2027Primary completion: phase 2 study in Breast NeoplasmsALX Oncology · NCT07007559
TargetBeta
“Leukocyte surface antigen CD47 inhibitor”ChEMBL 37, by rule
Other programs on CD47
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ligufalimabrule | Akeso | phase 3 | 11 |
| Anti-PD-1/CD47 Fusion Protein HX009rule | hangzhou-hanx-biopharmaceuticals-ltd | phase 2 | 5 |
| CD47 Antagonist AUR103 Calciumrule | Dr. Reddy's Laboratories | phase 2 | 2 |
| 1200mg of tqb2928 injection | Sino Biopharmaceutical | phase 1 | 2 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07007559Breast Neoplasms · United States, Canada, France and more | 2 | Recruiting | ALX Oncology | Dec 2027 | 120 |
| NCT05524545Urinary Bladder Neoplasms · United States | 1 | Completed | ALX Oncology | Jun 27, 2025 | 36 |
| NCT05027139HER2-expressing Cancers · United States | 2 | Completed | Jazz Pharmaceuticals | Aug 29, 2025 | 52 |
| NCT05002127Stomach Neoplasms · United States, Australia, Belgium and more | 3 | Completed | ALX Oncology | May 24, 2024 | 127 |
| NCT04755244Leukemia, Myeloid, Acute · United States | 1 | Terminated | ALX Oncology | May 5, 2023 | 14 |
| NCT04675333Head and Neck Neoplasms · United States, Australia, Belgium and more | 2 | Active, not recruiting | ALX Oncology | Mar 3, 2025 | 172 |
| NCT04675294Head and Neck Neoplasms · United States, Australia, Belgium and more | 2 | Active, not recruiting | ALX Oncology | Mar 3, 2025 | 189 |
| NCT04417517Higher Risk Myelodysplastic Syndromes · United States, South Korea, Spain | 1 | Terminated | ALX Oncology | Jan 17, 2025 | 65 |
| NCT03013218Neoplasm Metastasis · United States, South Korea | 1 | Completed | ALX Oncology | Feb 1, 2022 | 174 |
How it is read
Names in the registry
- “evorpacept”, 4 entries
- “Evorpacept (ALX148)”, 3 entries
- “Evorpacept”, 2 entries
Conditions, from the studies’ own filings
- Squamous Cell Carcinoma of Head and Neck, 2 studies
- Breast Neoplasms, 1 study
- Stomach Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
- Urinary Bladder Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.